FDA Approves New Potency Assay for Commercial Ryoncil

Skip to main navigation Home Company Overview Board of Directors Management Team Corporate Governance Contact Us Product Candidates Product Candidates Overview Cardiovascular Diseases Spine Orthopedic Disorders Oncology & Hematology Immune-Mediated & Inflammatory Conditions Clinical Trials Science Mesenchymal Lineage Cells Mechanisms of Action Manufacturing Intellectual Property Scientific Publications Partnerships Overview Investors & Media Investor Relations Company Announcements ASX Announcements Share Price & Tools Stock Quote & Chart Historical Lookup Calculator Events & Presentations Events Presentations Financial Information SEC Filings Annual Reports Financial Reports Analyst Coverage Earnings Estimates Financial Fundamentals Shareholder Services ADR Trading FAQs Information Request E-mail Alerts Careers Current Opportunities Home Contact Us Company Overview Board of Directors Management Team Corporate Governance Contact Us Product Candidates Product Candidates Overview Cardiovascular Diseases Spine Orthopedic Disorders Oncology & Hematology Immune-Mediated & Inflammatory Conditions Clinical Trials Science Mesenchymal Lineage Cells Mechanisms of Action Manufacturing Intellectual Property Scientific Publications Partnerships Overview Investors & Media Header investor menu Company Announcements Share Price & Tools Events and Presentations Financial Information Shareholder Services Careers Current Opportunities News Release FDA Approves New Potency Assay for Commercial Ryoncil September 24, 2026 at 9:52 AM AEST bfba2f97-cc09-439b-aa74-78cc14770b77.pdf 789.9 KB Investor Relations Company Announcements ASX Announcements Share Price & Tools Stock Quote & Chart Historical Lookup Calculator Events & Presentations Events Presentations Financial Information SEC Filings Annual Reports Financial Reports Analyst Coverage Earnings Estimates Financial Fundamentals Shareholder Services ADR Trading FAQs Information Request E-mail Alerts Tools Print Page RSS Feeds Email Alerts Share Price ASX: MSB.AX 2.04 as of Oct 02, 2026 Company Overview Board of Directors Management Team Corporate Governance Contact Us Product Candidates Product Candidates Overview Cardiovascular Diseases Spine Orthopedic Disorders Oncology Hematology Immune-Mediated & Inflammatory Conditions Clinical Trials Expanded Access Policy Science Mesenchymal Lineage Cells Mechanisms Of Action Manufacturing Intellectual Property Scientific Publications Partnerships Overview Careers Overview Board of Directors Management Team Corporate Governance Contact Us Investors & Media Header investor menu Company Announcements Share Price & Tools Events and Presentations Financial Information Shareholder Services Copyright © 2026 Mesoblast Ltd Disclaimer Privacy Policy Search